SCHEMBL2807050

SCHEMBL2807050

FC(F)(F)c1cccc(CNc2ncc3c(n2)CCc2cnc4[nH]ncc4c2-3)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 4/20 0.48
AXL P30530 2/20 0.44
TYRO3 Q06418 2/20 0.44
MERTK Q12866 2/20 0.44
IGF1R P08069 4/20 0.43
APP P05067 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PIP4K2A P48426 1/20 0.42
PIK3CG P48736 1/20 0.42
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
CLK1 P49759 1/20 0.41
DYRK1A Q13627 1/20 0.41
RPS6KB1 P23443 1/20 0.40
ROCK2 O75116 1/20 0.39
EGFR P00533 1/20 0.38
VNN1 O95497 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806333 0.83 RPS6KB1 (0.54) IGF1RRPS6KB1ROCK2EGFR
SCHEMBL2802228 0.82 AKT1 (0.38) RPS6KB1
SCHEMBL2802884 0.82 CDK2 (0.47) IGF1RHDAC3HDAC1HDAC2HDAC6
SCHEMBL2804059 0.81 DYRK1A (0.48) CLK1DYRK1ARPS6KB1ROCK2
SCHEMBL2803843 0.79 CCNA2 (0.42) IGF1RHDAC3HDAC1HDAC2HDAC6
SCHEMBL2802889 0.78 RPS6KB1 (0.43) IGF1RHDAC3HDAC1HDAC2HDAC6
SCHEMBL2803917 0.76 ALDH1A1 (0.42) IGF1RHDAC3HDAC1HDAC2HDAC6
SCHEMBL2806925 0.75 RPS6KB1 (0.39) HTR2CRPS6KB1
SCHEMBL2806420 0.73 CDK2 (0.39) RPS6KB1
SCHEMBL2486661 0.73 CCNA2 (0.38) HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 TDO2 2157/4885AXL 3510/4885TYRO3 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.